Brenus Pharma

Issoire, France Founded: 2020 • Age: 6 yrs
Immunotherapy for cancer treatment is developed by Brenus Pharma.
Request Access

About Brenus Pharma

Brenus Pharma is a company based in Issoire (France) founded in 2020.. Brenus Pharma has raised $25 million across 1 funding round from investors including Crédit Agricole, Angelor and UI Investissement. Brenus Pharma offers products and services including STC 1010 and STC Platform. Brenus Pharma operates in a competitive market with competitors including IGM Biosciences, Imvax, Check-Cap, BriaCell Therapeutics and New Element Medicine, among others.

  • Headquarter Issoire, France
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $25 M (USD)

    in 1 rounds

  • Latest Funding Round
    $25 M (USD), Series A

    Sep 18, 2024

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Brenus Pharma

Brenus Pharma offers a comprehensive portfolio of products and services, including STC 1010 and STC Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Immunotherapy targeting colorectal cancer to educate immune system against relapse.

Allogeneic system generating tumor antigen-focused treatments for solid tumors.

People of Brenus Pharma
Headcount 1-10
Employee Profiles 6
Board Members and Advisors 4
Employee Profiles
People
Lionel Chalus
Lead Technical Operations
People
Aymeric Bordet
Chief Financial Officer
People
Paul Bravetti
CEO
People
Benoit Pinteur
Founder & Chief Scientific Officer

Unlock access to complete

Board Members and Advisors
people
Pierre Morgon
Board Member
people
Laurence Comte Arassus
Board Member
people
Stéphane Loze
Board member
people
Hervé Gisserot
Board Member

Unlock access to complete

Funding Insights of Brenus Pharma

Brenus Pharma has successfully raised a total of $25M through 1 strategic funding round. The most recent funding activity was a Series A round of $25 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Series A — $25.0M
  • First Round

    (18 Sep 2024)

  • Investors Count 5
Date Amount Transaction Name Valuation Lead Investors Investors
Sep, 2024 Amount Series A - Brenus Pharma Valuation Angelor
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Brenus Pharma

Brenus Pharma has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Crédit Agricole, Angelor and UI Investissement. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
UI Investissement is engaged in private equity and investment services.
Founded Year Domain Location
Noshaq is recognized as a Liège-based investment fund providing financing solutions.
Founded Year Domain Location
Investsud is engaged in supporting SMEs with sustainable investments.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Brenus Pharma

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Brenus Pharma

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Brenus Pharma Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Brenus Pharma

Brenus Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as IGM Biosciences, Imvax, Check-Cap, BriaCell Therapeutics and New Element Medicine, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Antibodies for cancer and infectious disease treatments are developed.
domain founded_year HQ Location
Patient-specific cell vaccines for glioma treatment are developed.
domain founded_year HQ Location
Developer of imaging capsules for colorectal cancer screening
domain founded_year HQ Location
Developer of immunotherapies for the treatment of cancer
domain founded_year HQ Location
Drugs for cancer and metabolic diseases are developed.
domain founded_year HQ Location
Therapeutics for multiple diseases are developed using Aminoacyl-tRNA Synthetase technology.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Brenus Pharma

Frequently Asked Questions about Brenus Pharma

When was Brenus Pharma founded?

Brenus Pharma was founded in 2020 and raised its 1st funding round 4 years after it was founded.

Where is Brenus Pharma located?

Brenus Pharma is headquartered in Issoire, France. It is registered at Issoire, Auvergne-rhone-alpes, France.

Who is the current CEO of Brenus Pharma?

Jacques Gardette is the current CEO of Brenus Pharma.

Is Brenus Pharma a funded company?

Brenus Pharma is a funded company, having raised a total of $25M across 1 funding round to date. The company's 1st funding round was a Series A of $25M, raised on Sep 18, 2024.

What does Brenus Pharma do?

Brenus Pharma was founded in 2020 in Issoire, France, where focus is placed on biotechnology for oncology. Immunotherapy solutions are developed, with STC-1010 targeted at metastatic colorectal cancer and other solid tumors. Operations center on advancing clinical-stage treatments within the pharmaceutical sector, supporting research and development for cancer therapies across Europe.

Who are the top competitors of Brenus Pharma?

Brenus Pharma's top competitors include Imvax, IGM Biosciences and Check-Cap.

What products or services does Brenus Pharma offer?

Brenus Pharma offers STC 1010 and STC Platform.

Who are Brenus Pharma's investors?

Brenus Pharma has 5 investors. Key investors include Crédit Agricole, Angelor, UI Investissement, Noshaq, and Investsud.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available